Effectiveness of four inflammatory markers in predicting prognosis in 2374 women with breast cancer

Wariss, Bárbara Reis; Abrahão, Karen de Souza; Aguiar, Suzana Sales de; Bergmann, Anke; Thuler, Luiz Cláudio Santos

doi:10.1016/j.maturitas.2017.04.015

Cited by 34 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, a previous study showed that high ANC could be a poor prognostic marker in patients with breast cancer (24), supporting our findings that high ANC may negatively impact TILs in breast cancer. The association between NLR and TILs has not been identified, although NLR is a well-known poor prognostic marker in various cancers including breast cancer (9, 25–30).…”

Section: Discussionsupporting

confidence: 90%

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer

Yoon

Park

Jin

et al. 2019

Preprint

View full text Add to dashboard Cite

2Tumor-infiltrating lymphocytes (TILs) might be associated with host-cell mediated immunity, 3 which could be partly reflected by peripheral blood cell counts. We aimed to investigate 4 whether peripheral blood cell counts are associated with TILs in breast cancer. Between August 5 2016 and July 2018, we evaluated the percentage of stromal TILs in breast cancer patients who 6 underwent primary surgery, using the standardized methodology proposed by the international 7 TIL Working Group. Lymphocyte-predominant breast cancer (LPBC) was defined as tumors 8 having high TIL levels (≥ 50%). Peripheral blood cell counts including absolute neutrophil 9 counts (ANC), absolute lymphocyte counts (ALC) and neutrophil-to-lymphocyte ratio (NLR) 10 was obtained from pretreatment laboratory data. Of the 684 patients, 99 (17.2%) had LPBC, 11 and 478 (82.8%) had non-LBPC. In a comparison of 3 markers of peripheral blood counts, 12 LPBC had a significantly lower mean ANC than non-LPBC (3,330 vs. 3,660; P=0.004), but 13 the other means were not different. Decreasing ANC was an independent clinical factor in 14 predicting LPBC (OR: 0.736, 95% CI: 0.591-0.917; P=0.004). Low peripheral ANC might be 15 linked with LPBC, supporting the hypothesis that systemic immune cell counts might be 16 associated with the tumor-immune microenvironment.

show abstract

Section: Discussionsupporting

confidence: 90%

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer

Yoon

Park

Jin

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Histopathological and clinical examinations data were obtained for all patients. The exclusion criteria were as follows: (1) male breast carcinoma; (2) ductal carcinoma in situ or distant metastasis; (3) treatment with neoadjuvant chemotherapy or radiotherapy; (4) acute and/or chronic inflammatory, hematologic, or autoimmune diseases; (5) use of immunosuppressive or anti-inflammatory medicines; and (6) loss of complete laboratory data. Tumor staging was based on the 7th edition of the AJCC TNM staging system for breast cancer.…”

Section: Patientsmentioning

confidence: 99%

“…However, they are usually available for assessment until postoperatively. To determine more reliable and easily obtained prognostic markers, numerous preoperative markers have been comprehensively evaluated in several studies (5,6). Thus, far, there are few well-recognized preoperative biomarkers that have an independent prognostic value.…”

Section: Introductionmentioning

confidence: 99%

“…Studies examining the prognostic effects of inflammatory biomarkers in breast cancer have resulted in great improvements in recent years. C-reactive protein, lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), neutrophil-tolymphocyte ratio (NLR), and the prognostic nutritional index have been confirmed as potential independent prognostic factors in breast cancer (5,6,14,15). However, the prognostic value of the systemic immune-inflammation index (SII), combining lymphocyte, platelet, and neutrophil counts, has never been verified in breast cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Breast Cancer: A Propensity Score-Matching Study

et al. 2020

View full text Add to dashboard Cite

Purpose: It was reported that the novel preoperative systemic immune-inflammation index (SII) can predict survival in cases of many malignant tumors. However, the prognostic significance of preoperative SII in breast cancer remains unclear. The purpose of this study was to investigate the relationship between SII and survival in breast cancer patients.Methods: Breast cancer patients (1,026) who underwent a mastectomy at Sun Yat-sen University Cancer Center were retrospectively studied. The SII was determined using the following formula: neutrophil count × platelet count/lymphocyte count. The receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value for SII. Propensity score matching (PSM) was applied to develop comparable cohorts of high SII group and low SII group.Results: A total of 1,026 patients were included as the primary cohort, and 894 patients were matched and regarded as the matched cohort. Patients were divided into two groups based on SII value: SII<601.7 and high SII >601.7. In the primary cohort, the 5-years overall survival (OS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS) rates for high SII group and low SII group were (85.6% vs. 91.3%, P = 0.016), (95.8% vs. 96.4%, P = 0.684), and (83.5% vs. 90.6%, P = 0.007), respectively. Univariate analysis showed that histological type, T stage, N stage, PR, HER2, Ki67, and SII all showed significant associations with OS; and histological type, T stage, N stage, and SII all showed significant associations with DMFS. Multivariate survival analysis revealed that SII can independently predict OS (P = 0.017) and DMFS (P = 0.007). Similar results were found in PSM cohort.Conclusions: Preoperative SII may be a reliable predictor of OS and DMFS in patients with operable breast cancer to provide personalized prognostication and assist in formulation of the clinical treatment strategy.

show abstract

“…However, the current TNM stage system for CRC lacks information reflecting the inflammatory status in patients. There is now a growing consensus that the systemic inflammatory response is an independent risk factor for the development of malignancy and is associated with worse prognosis in various cancers, such as gastric cancer [5], pancreatic cancer [6], liver cancer [7], breast cancer [8], and esophageal cancer [9]. When cancer generates an inflammatory response, the levels of cytokines are increased and the phenotypes of immune cells are changed, which increase the propensity for tumor growth by promoting angiogenesis and drug therapy resistance, inhibiting apoptosis, and damaging DNA [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis

He¹,

Li²,

Cai³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Increasing evidence indicates that the systemic inflammatory response plays a vital role in carcinogenesis. The Glasgow Prognostic Score or modified Glasgow Prognostic Score (GPS/mGPS) is a novel inflammatory indicator which consists of CRP and albumin. Here, we performed a meta-analysis to evaluate the prognostic value of the GPS/ mGPS in patients with colorectal cancer (CRC) and to assess its consistency in different CRC therapies. Methods: The electronic databases PubMed, Embase, Scopus, Web of Science, and Cochrane Library were searched from inception through December 2017 for the association between the GPS/mGPS and clinical outcomes. Study characteristics and prognostic data were extracted from each relevant study. Overall survival (OS) and cancer-specific survival (CSS) were considered the primary outcomes, and hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. The quality of each study was pooled using the random-effects Mantel-Haenszel model. Finally, subgroup analyses were performed to detect the heterogeneity of different CRC treatments. Results: Thirty-four studies, with a combined total of 8834 patients, were eligible for this meta-analysis. Data on OS and CSS were available in 23 and 22 studies, respectively. By comparing the prognostic values of different levels of the GPS in CRC patients, the summary HRs for OS and CSS were 2.18 (95% CI 1.83-2.60) and 1.82 (95% CI 1.57-2.11), respectively. According to the different tumor stages, the subgroup analyses were stratified by different treatments, including curative or palliative therapy. The results robustly confirmed the prognostic role of the GPS/mGPS. Conclusion: Our results suggest that the GPS/mGPS is a novel and effective prognostic indicator for the OS and CSS of patients with CRC.

show abstract

Effectiveness of four inflammatory markers in predicting prognosis in 2374 women with breast cancer

Cited by 34 publications

References 26 publications

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer

Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Breast Cancer: A Propensity Score-Matching Study

Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About